This modified vaccinia virus Ankara (MVA) expressing a fusion gene of the CD4+ T-cell epitope-rich domain of EBNA1 and a full-length LMP2 was administered to 18 patients with advanced NPC, in the contest of a phase I trial. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.